A cell-based assay for the detection of neutralizing antibodies against alemtuzumab

AIM: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. RESULTS: Alemtuzumab–Alexa Fl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biotechniques
Hlavní autoři: Ali, Liaqat, Saxena, Gauri, Jones, Meleri, Leisegang, Georgia R, Gammon, Luke, Gnanapavan, Sharmilee, Giovannoni, Gavin, Schmierer, Klaus, Baker, David, Kang, Angray S
Médium: Artigo
Jazyk:Inglês
Vydáno: Future Science Ltd 2020
Témata:
Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7177201/
https://ncbi.nlm.nih.gov/pubmed/32096651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2144/btn-2019-0122
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky